bluebird bio Inc (NASDAQ:BLUE) Insider Sells $991,740.20 in Stock

Share on StockTwits

bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 7,660 shares of the stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $129.47, for a total transaction of $991,740.20. Following the completion of the transaction, the insider now owns 38,946 shares of the company’s stock, valued at approximately $5,042,338.62. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

David Davidson also recently made the following trade(s):

  • On Monday, May 6th, David Davidson sold 6,360 shares of bluebird bio stock. The shares were sold at an average price of $138.95, for a total transaction of $883,722.00.

NASDAQ:BLUE opened at $133.98 on Friday. bluebird bio Inc has a twelve month low of $87.49 and a twelve month high of $183.60. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.31 and a current ratio of 9.31. The firm’s 50-day simple moving average is $123.52. The company has a market cap of $7.33 billion, a price-to-earnings ratio of -12.54 and a beta of 2.30.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($2.99) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.79) by ($0.20). bluebird bio had a negative net margin of 1,184.01% and a negative return on equity of 34.01%. The business had revenue of $12.47 million for the quarter, compared to the consensus estimate of $15.49 million. During the same quarter last year, the business posted ($2.31) EPS. The business’s revenue for the quarter was down 21.9% on a year-over-year basis. As a group, equities analysts forecast that bluebird bio Inc will post -12.24 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Sphera Funds Management LTD. boosted its position in shares of bluebird bio by 77.0% during the 4th quarter. Sphera Funds Management LTD. now owns 138,796 shares of the biotechnology company’s stock valued at $13,769,000 after purchasing an additional 60,400 shares in the last quarter. Advisor Group Inc. boosted its position in shares of bluebird bio by 15.5% during the 4th quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 169 shares in the last quarter. Two Sigma Advisers LP bought a new position in shares of bluebird bio during the 4th quarter valued at about $4,385,000. Legal & General Group Plc boosted its position in shares of bluebird bio by 10.8% during the 4th quarter. Legal & General Group Plc now owns 26,564 shares of the biotechnology company’s stock valued at $2,636,000 after purchasing an additional 2,581 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of bluebird bio by 1.3% during the 4th quarter. California State Teachers Retirement System now owns 85,930 shares of the biotechnology company’s stock valued at $8,524,000 after purchasing an additional 1,065 shares in the last quarter.

A number of equities analysts recently issued reports on BLUE shares. Cantor Fitzgerald set a $122.00 target price on shares of bluebird bio and gave the company a “hold” rating in a research report on Friday, March 22nd. BidaskClub upgraded shares of Northrim BanCorp from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. Wedbush reiterated an “outperform” rating and issued a $124.00 target price on shares of New Relic in a research report on Wednesday, May 15th. Piper Jaffray Companies set a $120.00 target price on shares of bluebird bio and gave the company a “hold” rating in a research report on Friday, June 14th. Finally, Maxim Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and set a $160.00 target price for the company in a research report on Tuesday, June 18th. Ten research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. bluebird bio currently has a consensus rating of “Buy” and an average price target of $162.49.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

See Also: What is a capital gains distribution?

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.